Q-omics provides the consensus-scored LOXL1 profile across patient tissues and cancer cell-line models. LOXL1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LOXL1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, LOXL1 protein abundance shows 29,412 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight MESO, HNSC, and BRCA as cancer lineages where LOXL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LOXL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LOXL1 survival associations across molecular data types. LOXL1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LOXL1 RNA expression–survival associations across cancer types. High LOXL1 expression shows unfavorable associations in MESO, KIRC, LGG and GBM, but favorable associations in HNSC and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LOXL1 RNA expression.
This table summarizes LOXL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LOXL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LOXL1 shows higher tumor expression in HNSC, LUAD, COAD, STAD, BRCA and LUSC. The HNSC box plot shows higher LOXL1 RNA expression in tumor versus normal tissue (log2 FC = +1.277, t-test p < 0.001).
This table shows molecular features associated with LOXL1 in patient tissues and cancer cell lines. In patient samples, LOXL1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LOXL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
